Black Diamond Therapeutics Inc

Job Listings


Here are our current job openings. Please click on the job title for more information, and apply from that page if you are interested.

Use this form to perform another job search

The system cannot access your location for 1 of 2 reasons:
  1. Permission to access your location has been denied. Please reload the page and allow the browser to access your location information.
  2. Your location information has yet to be received. Please wait a moment then hit [Search] again.
Click column header to sort

Search Results Page 1 of 1

Job Locations US-MA-Cambridge
Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers for whom limited treatment options currently exist. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Company’s proprietary technology platform, Mutation-Allostery-Pharmacology, or MAP, platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families and develop a single small molecule therapy in a tumor-agnostic manner that targets a specific family of mutations   The Head of Technical Operations will be responsible for Black Diamond’s manufacturing & supply chain strategy, including CMC/early development, for all development programs in preparation for commercialization and in support of the Company’s corporate objectives and strategy.   Key aspects of the role include ensuring clinical supply for on-going clinical trials, building out manufacturing resources and capabilities, identifying and securing key supplier relationships, preparing for and supporting regulatory filings and interactions, and preparing for commercialization based on accelerated approval pathways.  The successful candidate enjoys the environment of an early-stage clinical biotech company and alternating between being “hands-on” and strategic.
Category
Clinical Development-Clinical Operations
ID
2020-1038
Job Locations US-MA-Cambridge
  Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers for whom limited treatment options currently exist. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Company’s proprietary technology platform, Mutation-Allostery-Pharmacology, or MAP, platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families and develop a single small molecule therapy in a tumor-agnostic manner that targets a specific family of mutations.   Black Diamond is currently seeking a DMPK project representative. Reporting to the Director, DMPK, the incumbent will be the drug metabolism and pharmacokinetics (DMPK) lead on project teams developing small molecule modulators as precision cancer medicines. We are looking for a consummate team player seeking a collaborative environment in which to grow their career in drug discovery and development.  
Category
Research - Chemistry
ID
2020-1037
Job Locations US-MA-Cambridge
Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers for whom limited treatment options currently exist. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Company’s proprietary technology platform, Mutation-Allostery-Pharmacology, or MAP, platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families and develop a single small molecule therapy in a tumor-agnostic manner that targets a specific family of mutations. The Medical Director will be responsible for clinical research activities pertaining to Black Diamond's lead clinical asset, BDTX-189 as well as future clinical candidates as they move from discovery into IND-enabling activities. The Medical Director will engage relevant scientific/medical experts and key opinion leaders in order to manage clinical data generation from company-sponsored trials and other sources with the goal of obtaining regulatory approval for patients with an unmet medical need. The ideal candidate will be a medical oncologist or equivalent with a proven track-record in leading targeted therapy clinical protocols in patients with relevant solid tumors.  The role will have the opportunity to contribute on the clinical development of novel drug candidates intended to treat patients in a tumor agnostic fashion. 
Category
Clinical Development
ID
2020-1036
Job Locations US-MA-Cambridge
Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers for whom limited treatment options currently exist. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Company’s proprietary technology platform, Mutation-Allostery-Pharmacology, or MAP, platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families and develop a single small molecule therapy in a tumor-agnostic manner that targets a specific family of mutations   The VP - Head of Quality Assurance is responsible for the strengthening and further development and execution of the Company’s quality assurance program and systems, in support of all drug development and manufacturing activities, directing cGxP quality related activities across the organization to support global regulatory submissions (NDA/MAA, etc) and ultimately commercial launch of products. The VP will build an internal team and relationships with external consultants/contractors, as necessary to support QA activities and responsibilities and provide leadership and guidance to the organization on global quality matters. This position requires expertise in current Good Manufacturing Processes (GMP), Good Clinical Practices (GCP), Good Pharmacovigilance Practices (GVP), and Good Laboratory Practices (GLP) and relevant regulations.  
Category
Business Operations
ID
2020-1035
Job Locations US-MA-Cambridge
Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers for whom limited treatment options currently exist. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Company’s proprietary technology platform, Mutation-Allostery-Pharmacology, or MAP, platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families and develop a single small molecule therapy in a tumor-agnostic manner that targets a specific family of mutations.   The BDTX Clinical Trial Associate (CTA) role collaborates with cross-functional team members to assist the clinical research teams in ensuring the most effective and efficient conduct of clinical research studies by providing administrative and project tracking support.
Category
Clinical Development
ID
2020-1034
Job Locations US-MA-Cambridge
Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers for whom limited treatment options currently exist. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Company’s proprietary technology platform, Mutation-Allostery-Pharmacology, or MAP, platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families and develop a single small molecule therapy in a tumor-agnostic manner that targets a specific family of mutations.   The BDTX Medical Writer role collaborates with cross-functional team members to develop high-quality clinical study protocols (CSP), investigator brochures, synopses, Clinical Study Reports (CSRs), regulatory documents, clinical publications, and other related clinical documents within the project timelines.
Category
Clinical Development-Clinical Operations
ID
2020-1033
Job Locations US-NY-New York
Black Diamond Therapeutics  Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers for whom limited treatment options currently exist. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Company’s proprietary technology platform, Mutation-Allostery-Pharmacology, or MAP, platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families and develop a single small molecule therapy in a tumor-agnostic manner that targets a specific family of mutations. Black Diamond has an exciting opening for an experienced cancer biologist to serve as Director – Discovery Biology at the research site located in New York City. Reporting to the VP of Discovery Biology, the incumbent will lead a biology team and drive drug discovery projects through close collaboration with others to reshape and extend the pipeline of precision oncology medicines.
Category
Research-Biology
ID
2019-1026
Job Locations US-MA-Cambridge
Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers for whom limited treatment options currently exist. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Company’s proprietary technology platform, Mutation-Allostery-Pharmacology, or MAP, platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families and develop a single small molecule therapy in a tumor-agnostic manner that targets a specific family of mutations.   The Project Manager will provide project management support on drug discovery and development project teams. The Project Manager will actively contribute and help the teams to effectively and efficiently deliver on project goals on schedule and within budget. The Project Manager will contribute to the functional development of project management at Black Diamond.
Category
Research - Project Management
ID
2019-1015
Job Locations US-MA-Cambridge
Black Diamond Therapeutics is a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies. Black Diamond targets undrugged mutations in patients with genetically defined cancers for whom limited treatment options currently exist. Black Diamond is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. The Company’s proprietary technology platform, Mutation-Allostery-Pharmacology, or MAP, platform, is designed to allow Black Diamond to analyze population-level genetic sequencing data to identify oncogenic mutations that promote cancer across tumor types, group these mutations into families and develop a single small molecule therapy in a tumor-agnostic manner that targets a specific family of mutations. This position will support the Chief Operating Officer and General Counsel and requires a high degree of flexibility, judgment, organizational and technical skills.
Category
Business Operations
ID
2019-1014